Fluvoxamine

Generic Name: Fluvoxamine

Brand Names: Luvox

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₁F_₃N_₂O_₂

CAS Number: 54739-18-3

Unique Ingredient Identifier: O4L1XPO44W

Background: Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
...

Indication: Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) . Has also been used in the management of bulimia nervosa .

Associated Conditions: Bulimia Nervosa, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine

Phase 4

Completed

Conditions: Recurrent Depressive Disorder

Interventions: Drug: Fluvoxamine

First Posted Date: 2013-12-19

Last Posted Date: 2015-07-21

Lead Sponsor: Moscow Research Institute of Psychiatry

Target Recruit Count: 50

Registration Number: NCT02016261

Locations: 🇷🇺
Moscow Research Institution of Psychiatry, Moscow, Russian Federation

A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder

Phase 3

Completed

Conditions: Obsessive Compulsive Disorder

Interventions: Drug: Fluvoxamine maleate
Drug: Placebo

First Posted Date: 2013-09-02

Last Posted Date: 2017-12-04

Lead Sponsor: AbbVie

Target Recruit Count: 38

Registration Number: NCT01933919

Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics of Quetiapine

Interventions: Drug: FK949E
Drug: fluvoxamine

First Posted Date: 2013-07-25

Last Posted Date: 2017-02-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT01908296

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date: 2013-07-11

Last Posted Date: 2013-07-11

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 74

Registration Number: NCT01896349

Locations: 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients

Not Applicable

Conditions: SCHIZOPHRENIA 1 (Disorder)

Interventions: Drug: fluvoxamine

First Posted Date: 2013-04-16

Last Posted Date: 2013-04-23

Lead Sponsor: Sha'ar Menashe Mental Health Center

Target Recruit Count: 40

Registration Number: NCT01832285

Locations: 🇮🇱
Shaar Menashe Mental Health Center, Hadera, Ha Sharon, Israel

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Phase 4

Conditions: Major Depressive Disorder

Interventions: Drug: Escitalopram
Drug: Fluoxetine
Drug: Mirtazapine
Drug: Citalopram
Other: modified electroconvulsive therapy
Other: repetitive transcranial magnetic stimulation
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Venlafaxine
Drug: Duloxetine
Drug: Bupropion
Drug: Trazodone

First Posted Date: 2013-01-10

Last Posted Date: 2013-01-10

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 1080

Registration Number: NCT01764867

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy
Pharmacology, Clinical

Interventions: Drug: Pomalidomide
Drug: Ketoconazole
Drug: Carbamazepine
Drug: Fluvoxamine

First Posted Date: 2012-10-16

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT01707407

Locations: 🇺🇸
Covance Research Unit, Inc, Madison, Wisconsin, United States

Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes

Phase 1

Completed

Conditions: Depression

Interventions: Drug: fluvoxamine
Drug: Digoxin

First Posted Date: 2012-10-11

Last Posted Date: 2015-09-01

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 14

Registration Number: NCT01704638

Locations: 🇸🇪
CPTU, Stockholm, Sweden

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

Phase 1

Completed

Conditions: Advanced Solid Tumors, Excluding Breast Cancer

Interventions: Drug: dovitinib (TKI258)
Drug: fluvoxamine

First Posted Date: 2012-10-04

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT01700270

Locations: 🇨🇭
Novartis Investigative Site, Genève, Switzerland
🇺🇸
Montefiore Medical Center Montefiore Medical Center (SC), Bronx, New York, United States
🇺🇸
Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio, Texas, United States

A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO4917523
Drug: Fluvoxamine

First Posted Date: 2012-08-15

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT01665404

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy